Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting

Massimiliano Papi; D. Pozzi; V. Palmieri; G. Caracciolo

doi:10.1016/j.nantod.2022.101403

Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting

Massimiliano Papi
, D. Pozzi
, V. Palmieri^*
, G. Caracciolo

^*Corresponding author

Sapienza University
Institute for Polymers

Research output: Contribution to journal › Article

Abstract

BioNTech/Pfizer's Comirnaty and Moderna's SpikeVax vaccines consist in mRNA encapsulated in lipid nanoparticles (LNPs). The modularity of the delivery platform and the manufacturing possibilities provided by microfluidics let them look like an instant success, but they are the product of decades of intense research. There is a multitude of considerations to be made when designing an optimal mRNA-LNPs vaccine. Herein, we provide a brief overview of what is presently known and what still requires investigation to optimize mRNA LNPs vaccines. Lastly, we give our perspective on the engineering of 3D bioprinted validation systems that will allow faster, cheaper, and more predictive vaccine testing in the future compared with animal models.

Original language	English
Pages (from-to)	N/A-N/A
Journal	Nano Today
Volume	43
Issue number	n/a
DOIs	https://doi.org/10.1016/j.nantod.2022.101403
Publication status	Published - 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Biotechnology
Bioengineering
Biomedical Engineering
General Materials Science
Pharmaceutical Science

Keywords

Administration route
Bioprinting
COVID-19
Lipid nanoparticles
Vaccines
mRNA

Access to Document

10.1016/j.nantod.2022.101403

Cite this

@article{386e25119f444aefaa89035c727a8245,

title = "Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting",

abstract = "BioNTech/Pfizer's Comirnaty and Moderna's SpikeVax vaccines consist in mRNA encapsulated in lipid nanoparticles (LNPs). The modularity of the delivery platform and the manufacturing possibilities provided by microfluidics let them look like an instant success, but they are the product of decades of intense research. There is a multitude of considerations to be made when designing an optimal mRNA-LNPs vaccine. Herein, we provide a brief overview of what is presently known and what still requires investigation to optimize mRNA LNPs vaccines. Lastly, we give our perspective on the engineering of 3D bioprinted validation systems that will allow faster, cheaper, and more predictive vaccine testing in the future compared with animal models.",

keywords = "Administration route, Bioprinting, COVID-19, Lipid nanoparticles, Vaccines, mRNA, Administration route, Bioprinting, COVID-19, Lipid nanoparticles, Vaccines, mRNA",

author = "Massimiliano Papi and D. Pozzi and V. Palmieri and G. Caracciolo",

year = "2022",

doi = "10.1016/j.nantod.2022.101403",

language = "English",

volume = "43",

pages = "N/A--N/A",

journal = "Nano Today",

issn = "1748-0132",

publisher = "Elsevier B.V.",

number = "n/a",

}

TY - JOUR

T1 - Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting

AU - Papi, Massimiliano

AU - Pozzi, D.

AU - Palmieri, V.

AU - Caracciolo, G.

PY - 2022

Y1 - 2022

N2 - BioNTech/Pfizer's Comirnaty and Moderna's SpikeVax vaccines consist in mRNA encapsulated in lipid nanoparticles (LNPs). The modularity of the delivery platform and the manufacturing possibilities provided by microfluidics let them look like an instant success, but they are the product of decades of intense research. There is a multitude of considerations to be made when designing an optimal mRNA-LNPs vaccine. Herein, we provide a brief overview of what is presently known and what still requires investigation to optimize mRNA LNPs vaccines. Lastly, we give our perspective on the engineering of 3D bioprinted validation systems that will allow faster, cheaper, and more predictive vaccine testing in the future compared with animal models.

AB - BioNTech/Pfizer's Comirnaty and Moderna's SpikeVax vaccines consist in mRNA encapsulated in lipid nanoparticles (LNPs). The modularity of the delivery platform and the manufacturing possibilities provided by microfluidics let them look like an instant success, but they are the product of decades of intense research. There is a multitude of considerations to be made when designing an optimal mRNA-LNPs vaccine. Herein, we provide a brief overview of what is presently known and what still requires investigation to optimize mRNA LNPs vaccines. Lastly, we give our perspective on the engineering of 3D bioprinted validation systems that will allow faster, cheaper, and more predictive vaccine testing in the future compared with animal models.

KW - Administration route

KW - Bioprinting

KW - COVID-19

KW - Lipid nanoparticles

KW - Vaccines

KW - mRNA

KW - Administration route

KW - Bioprinting

KW - COVID-19

KW - Lipid nanoparticles

KW - Vaccines

KW - mRNA

UR - https://publicatt.unicatt.it/handle/10807/302926

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85123777196&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85123777196&origin=inward

U2 - 10.1016/j.nantod.2022.101403

DO - 10.1016/j.nantod.2022.101403

M3 - Article

SN - 1748-0132

VL - 43

SP - N/A-N/A

JO - Nano Today

JF - Nano Today

IS - n/a

ER -

Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this